Publicaties

Kraan AEM, Dijkstra BAG, Markus W.  2018.  Treatment delivery of the community reinforcement approach in outpatient addiction treatment.. Eval Program Plann. 70:61-66.

Koster RA, Alffenaar JWC, Greijdanus B, VanDerNagel JEl, Uges DRA.  2014.  Fast and Highly Selective LC-MS/MS Screening for THC and 16 Other Abused Drugs and Metabolites in Human Hair to Monitor Patients for Drug Abuse.. Ther Drug Monit. 36(2):234-43.

Koster RA, Alffenaar JWC, Greijdanus B, VanDerNagel JEl, Uges DRA.  2014.  Application of sweat patch screening for 16 drugs and metabolites using a fast and highly selective LC-MS/MS method.. Ther Drug Monit. 36(1):35-45.

Kok T, de Haan HA, van der Velden HJ, van der Meer M, Najavits LM, DeJong CA.  2012.  Validation of two screening instruments for PTSD in Dutch substance use disorder inpatients. Addict Behav. 38(3)

Kok T, de Haan HA, van der Meer M, Najavits LM, DeJong CA.  2013.  Efficacy of "seeking safety" in a Dutch population of traumatized substance-use disorder outpatients: study protocol of a randomized controlled trial.. BMC Psychiatry. 13:162.

Kok T, de Haan HA, Wieske E, van Oene GH de Weert, DeJong CA.  2015.  Screening For Personality Disorders in Outpatient Substance Use Disorder Patients. European Journal of Psychological Assessment.

Kok T, van Rens L, de Haan HA.  2013.  Posttraumatische stressstoornis en verslaving. Handboek Dubbele Diagnose.

Kok T., de Haan H.A., Sensky T., van der Meer M., De Jong C.A.J..  2017.  Using the Pictorial Representation of Illness and Self Measure (PRISM) to Quantify and Compare Suffering From Trauma and Addiction.. Journal of Dual Diagnosis . 13(2)

Kok T, de Haan HA, van der Velden HJW, van der Meer M, Najavits LM, DeJong CA.  2013.  Validation of two screening instruments for PTSD in Dutch substance use disorder inpatients.. Addict Behav. 38(3):1726-31.

Kok T, de Haan HA, van der Meer M, Najavits LM, DeJong CA.  2014.  Screening of current PTSD in substance use disorder patients with the Depression, Anxiety and Stress Scale (DASS-21): a reliable and convenient measure. European Addiction Research.

Kok T..  2017.  Using the Pictorial Representation of Illness and Self Measure (PRISM) toe Quantify and Compare Suffering From Trauma and Addiction. Journal of Dual Diagnosis. 13(2)

Kok T, de Haan HA, van der Meer M, Najavits L, DeJong CA.  2015.  Assessing traumatic experiences in screening for PTSD in substance use disorder patients: What is the gain in addition to PTSD symptoms? Psychiatry Res. 226(1):328-32.

Kok T, de Haan HA, van der Meer M, Najavits LM, DeJong CA.  2015.  Screening of current post-traumatic stress disorder in patients with substance use disorder using the Depression, Anxiety and Stress Scale (DASS-21): a reliable and convenient measure.. Eur Addict Res. 21(2):71-7.

Knuijver T, Belgers M, Markus W, Verkes R-J, van Oosteren T, Schellekens AFA.  2018.  Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence. J Clin Psychopharmacol. 38(6):646-648.

Klaassen R., van Delden R., VanDerNagel JEL, Kamp M., Thio B., Heylen D..  2019.  In body experiences: Persuasion by doing. CEUR workshop proceedings. 2340

Kisjes H., Verbrugge C, DeJong CA.  2012.  Begeleiding en behandeling bij verslavingsproblematiek. Leerboek psychiatrie voor verpleegkundigen.

Kisjes H, Verbrugge C.  2012.  Begeleiding en behandeling bij verslavingsproblematiek. Leerboek Sociaal Pedagogische Hulpverlening.

Kisjes H., Verbrugge C, DeJong CA.  2015.  Begeleiding en behandeling bij verslavingsproblematiek. Psychiatrie voor verpleegkundigen. :253-273.

Kiewik M, VanDerNagel JEl, Engels RCME, DeJong CA.  2017.  Intellectually disabled and addicted: a call for evidence based tailor-made interventions.. Addiction. 112(11):2067-2068.

Kiewik M, VanDerNagel JEl, Kemna L.E.M., Engels RCME, DeJong CA.  2016.  Substance use prevention program for adolescents with intellectual disabilities on special education schools: A cluster randomised control trial. Journal of Intellectual Disability Research. 60(3):191–200.

Kiewik M, VanDerNagel JEl, Kemna LEM, Engels RCME, DeJong CA.  2016.  Substance use prevention program for adolescents with intellectual disabilities on special education schools: a cluster randomised control trial.. J Intellect Disabil Res. 60(3):191-200.

Kiewik M, VanDerNagel JEl, Engels RCME, DeJong CA.  2017.  The efficacy of an e-learning prevention program for substance use among adolescents with intellectual disabilities: A pilot study.. Res Dev Disabil. 63:160-166.

Kiewik M, VanDerNagel JEl, Thijs AL.  2014.  Chronisch alcoholmisbruik bij mensen met een licht verstandelijke beperking. Nurse Academy. 1

Kamal RM, Qurishi R, DeJong CA.  2015.  Baclofen and γ-Hydroxybutyrate (GHB), a Dangerous Combination.. J Addict Med. 9(1):75-7.

Kamal RM, Loonen AJ, Dijkstra BAG, DeJong CA.  2015.  Baclofen as relapse prevention in the treatment of gamma-hydroxybutyrate dependence: a case series.. J Clin Psychopharmacol. 35(3):313-8.